BAY2965501
- Generic Name
- BAY2965501
A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 284
- Registration Number
- NCT05614102
- Locations
- 🇬🇧
Oxford University Hospitals NHS Foundation Trust | Churchill Hospital - Oncology, Oxford, Oxfordshire, United Kingdom
🇺🇸Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath